| Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study |
|
Blood Cancer Journal |
Myelodysplastic Syndromes (MDS) |
| Terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high-dose eculizumab to ravulizumab: a phase IV, single-arm clinical trial |
|
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Infections in lower-risk myelodysplastic syndromes - prevalence and risk factors: a report from the European MDS Registry |
|
Haematologica |
Myelodysplastic Syndromes (MDS) |
| Patient-reported improvements in paroxysmal nocturnal hemoglobinuria treated with iptacopan from 2 phase 3 studies |
|
Blood Advances |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Thrombosis at Unusual Sites: Focus on Myeloproliferative Neoplasms and Paroxysmal Nocturnal Hemoglobinuria |
|
Hamostaseologie |
Myeloproliferative Neoplasms (MPN), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Elderly Patients With Aplastic Anemia: Treatment Patterns and Outcomes in the Real World |
|
American Journal of Hematology |
Aplastic Anemia |
| Initial management of patients with acquired aplastic anemia in the United States: results from a large national claims database |
|
Annals of Hematology |
Aplastic Anemia |
| New Approvals in Low- and Intermediate-Risk Myelodysplastic Syndromes |
|
American Society of Clinical Oncology Educational Book |
Myelodysplastic Syndromes (MDS) |
| Disease Burden at the Time of Transplantation Is a Primary Predictor of Outcomes in Pediatric MDS: A Single-Center Experience |
|
Cancers |
Myelodysplastic Syndromes (MDS), Pediatric |
| The Advancing Landscape of Paroxysmal Nocturnal Hemoglobinuria Treatment |
|
Turkish Journal of Haematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
